Research programme: anti-infectives - Genelabs Technologies

Drug Profile

Research programme: anti-infectives - Genelabs Technologies

Alternative Names: Anti-infectives research programme - Genelabs; DNA-binding polyheterocyclic compounds - Genelabs; GL 047374; GL 118172; GL 243287; GL 359986; GL 478057; GL 48087; GL 521997; GL 548043; GL 568816; GL 579225; GL 663142; GL 700241; GL 701649; GL 703027; GL 832293; GL 886217; GL 898298; Pyrrole tetraamides research programme - Genelabs

Latest Information Update: 04 Mar 2008

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Genelabs Technologies
  • Class Amides; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Bacterial infections; Mycoses

Most Recent Events

  • 18 Nov 2004 Discontinued - Preclinical for Bacterial infections in USA (unspecified route)
  • 14 Jun 2002 Preclinical trials in Mycoses in USA (unspecified route)
  • 07 Mar 2002 Early research in Bacterial infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top